ClinicalTrials.gg
Enrolling by invitationNCT05842733Updated Jul 27, 2023

A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management

A Phase 2 interventional study of Naldebain and SafeTynadol in Pain, Postoperative, sponsored by Sinew Pharma Inc.. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Sinew Pharma Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing nalbuphine sebacate in Pain, Postoperative — 3 open to participants now, 3 under way, 1 of them phase 3. nalbuphine sebacate · Pain, Postoperative.

Planned enrollment
11th of 11
36 · median 78
Started
2023
with 1 other
Phase 2
2 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Sinew Pharma Inc.

Among the 11 studies testing nalbuphine sebacate in Pain, Postoperative, this one is the 11th largest by planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 9th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 11 studies testing nalbuphine sebacate in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About nalbuphine sebacate

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nalbuphine sebacate in Pain, Postoperative, or all of them as a file.
02

Study summary

To assess the safety, efficacy, and pharmacokinetics of oral SafeTynadol, Naldebain and Naldebain combine with SafeTynadol in the treatment of moderate to severe pain following knee replacement.

Read the detailed description

Randomized, double-blind, parallel-group, 3-arm, oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

The complete evaluable 36 subjects (12 subjects in each group) will be analysis in this study. The experiment is divided into three groups of 12 people each. All subjects will be evaluated pharmacokinetics by drawing blood single point at 70.75 ± 2 hours after the first dose..

The population for this study in patients scheduled for knee replacement.

Each group of 12 subjects are administered group 1-3 from day 1-4 after surgery. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose. Mode of administration of oral Naldebain 37.5 mg (0.5 mL oil solution) or Placebo B (0.5 mL oil solution) is withdrawing 0.5 mL of Naldebain 37.5 mg (0.5 mL oil solution) or Placebo B (0.5 mL oil solution) from the vial by a syringe, then is injected into the empty capsule and dispense within 10 minutes prior to dosing.

Screening (Days -30 to -1) (All Study Subjects)

The nature of the study as well as the potential risks and benefits associated with study participation will be fully explained to all potential subjects. The following will then be obtained:

  1. Informed consent.
  2. Demographic information, including height and weight.
  3. Vital signs (temperature, respiratory rate, blood pressure and heart rate).
  4. Medical history, including medication use.
  5. Complete physical examination including 12-lead ECG.
  6. Laboratory testing (blood 50 ± 5 mL) to include the following:

    1. CBC with differential, platelets, White blood cell count (WBC), Red blood cell count (RBC), Hemoglobin, Hematocrit, Mean cell volume (MCV), Mean cell hemoglobin (MCH), Mean cell hemoglobin concentration (MCHC), Platelet count, Differential white cell count.
    2. Blood chemistry screen (Glucose, AST, ALT, BUN, creatinine, K, Na, Antibody screening, ABO Grouping \& RH Type, Activated partial thromboplastin time, Prothrombin time).
    3. Galactose single-point (GSP) test.
    4. Urine pregnancy test (female only) (not applicable to female who has stopped menstruating for at least five years).
  7. CHEST PA VIEW

Study Day -1

Subjects will be required to check into the clinical site before surgery (Day -1). The following procedures will be performed:

  1. Physical examination.*
  2. Vital signs.*
  3. Urine pregnancy test (female only) (not applicable to female who has stopped menstruating for at least five years).*
  4. Review of concomitant medications.*
  5. Blood (8 ± 3 mL) will be obtained to assess SDE, nalbuphine, AAP and metabolites (AAP-Sul, AAP-Glc, AAP-Cys, AAP-Nac and APAP-protein adducts) concentrations.

    • If the screening test items are performed in Day -1, the repeat test items only need to be tested once.

Study Day 1-4

All subjects will be given regional anesthesia and be preferentially randomized into one of group 1-3. The study drug will be administered 1-4 days after surgery. First dose of study medication is given 2 ± 2 hours after surgery. Total trial drug will be giving eight times. Each group of 12 subjects are administered group 1-3 from day 1-4 after surgery.

Group 1: Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

Group 2: Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 25, 58 ± 2 and 70 ± 2 hours after the first dose.

Group 3: Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

After surgery, the following evaluations will be performed.

  1. Pain assessment: All subjects will assess their average pain intensity using a VAS pain scale. The VAS pain scale assessment will start at 0 ± 0.5, 2 ± 0.5, 4 ± 0.5, 6 ± 2, 10 ± 25, 14 ± 2, 22 ± 2, 28 ± 2, 34 ± 2, 46 ± 2, 52 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
  2. Blood draw (5 ± 3 mL) for assessment of liver chemistry tests (ALT and AST) at 1 ± 0.5 hours after the first oral administration. If significant hepatotoxicity occurs (ALT or AST level more than 5 folds of ULN (upper limit of normal); or ALT or AST level more than 3 folds of ULN with signs of hepatitis, such as jaundice; or ALT or AST > 1000IU), subject needs to withdraw.
  3. VAS score assessed for three times in 5-minut e intervals before giving rescue medication. The VAS score is greater than 7 at least two times. VAS score assessed before giving rescue medication as VAS score for the remaining assessments.
  4. When the subject takes the study medication or rescue medication, and request further rescue medication. VAS score assessed for three times in 5-minute intervals before giving rescue medication. The VAS score has to greater than 7 at least two times. Rescue medication will be given in the order of (1) to (2). The interval between rescue medications should be at least 1 hour.
  5. If the subject requests rescue medicine, the group 1-3 will receive sequence of rescue medications follow the (1) IV Parecoxib 40 mg Q12H and (2) IV morphine 4 mg Q4H PRN.The above method of administration shall be carried out according to the procedure of administration in the hospital ward.
  6. Recorded the first time to IV Parecoxib 40 mg and IV morphine 4 mg, and then the amount and frequency of the medications' use within 72 hours will be recorded.
  7. Blood draw (8 ± 3 mL) for assessment of SDE, nalbuphine, acetaminophen and metabolites (AAP-Sul, AAP-Glc, AAP-Cys, AAP-Nac and APAP-protein adducts) concentrations before giving the first time's rescue medicationor termination or withdrawals.
  8. Vital signs (temperature, respiratory rate, blood pressure and heart rate) will be checked at 0 ± 0.5, 2 ± 0.5, 4 ± 0.5, 6 ± 2, 10 ± 2, 14 ± 2, 22 ± 2, 28 ± 2, 34 ± 25, 46 ± 2, 52 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
  9. The evaluation of adverse events will continue until the end of the trial 120 hours after the first dose.
  10. Review of concomitant medications.
  11. Using Brief Pain Inventory short form (BPIsf) to assess pain intensity and pain interference at 22 ± 2, 46 ± 2 and 70 ± 2 hours after the first dose.

On Day 4, following evaluations will be performed:

  1. Review of adverse events.
  2. Review of concomitant medications.
  3. Blood draw (8 ± 3 mL) for assessment of SDE, nalbuphine, acetaminophen and metabolites (AAP-Sul, AAP-Glc, AAP-Cys, AAP-Nac and APAP-protein adducts) concentrations at 70.75 ± 2 hours after the first dose in all subjects and Blood draw (20 ± 3 mL) for CBC with differential, platelets and blood chemistry screen (Not include Antibody screening and ABO Grouping \& RH Type determination). The blood collection time is carried out according to the routine blood drawing procedure in the hospital ward.
  4. Physical examination, including vital signs and 12-lead ECG.
  5. Patient satisfaction.
  6. Galactose single-point (GSP) test.

Follow-up visit:

24 and 48 hours after the subject took the last medication then researchers conduct telephone interviews to track the overall condition of the subject.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • SafeTynadol
  • Naldebain
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≧ 20 years of age at Screening.
  • Knee replacement patients.
  • American Society of Anesthesiology Physical Class 1 and 2.
  • Ability and willingness to provide , adhere to the study visit schedule and complete all study assessments and language specific questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Body weight less than 50 kg.
  • Subject is pregnant or breastfeeding. Women of have a positive urine pregnancy test at baseline.
  • Women of childbearing potential disagree to use an acceptable method of (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the study.
  • History of or allergy to amide-type local anesthetics, opioid, acetaminophen, or any ingredient of the medications administered in this study.
  • Subject has a resting respiratory rate less than 8 per minute and blood oxygen saturation less than 90 %.
  • Administration of an drug within 5 elimination half-lives of such investigational drug prior to study drug administration.
  • The investigator judged that any psychiatric disorder or psychological condition that may interfere with study assessments or compliance.
  • History of abuse illicit medications, prescription medicines or alcohol within the past 2 years. History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120 mL wine or 14 cans of 350 mL beer).
  • Current painful physical condition other than knee pain.
  • The investigator judged that the sensory nerve examination results were abnormal before the knee replacement in this trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Naldebain

    Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

    Drug: Naldebain

  • Active comparator
    SafeTynadol

    Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

    Drug: SafeTynadol

  • Active comparator
    Naldebain + SafeTynadol

    Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 25 hours after the first dose.

    Drug: Naldebain + SafeTynadol

Interventions

  • DrugNalbuphine sebacateStudies of Nalbuphine sebacateNalbuphine sebacate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

    Also known as: Placebo A + Tween20 and PEG400

  • DrugSafeTynadol

    Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

    Also known as: Placebo B + Tween20 and PEG400

  • DrugNaldebain + SafeTynadol

    Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0(2 ± 2 hour after surgery), 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.

    Also known as: Tween20 and PEG400

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of visual analogue scale

    Pain assessment calculated as the area under the curve (AUC) of visual analogue scale (VAS, 0-100 mm) pain intensity scores through 70 ± 2 hours after the first dose.

    Time frame: 0 hour - 70 hours after first dose

Secondary outcomes

  1. The first time using any one kind of rescue medication

    1. The first time using any one kind of rescue medication, in which the first-line rescue medication parecoxib 40 mg and second-line rescue medication morphine 4 mg.

    Time frame: Day 1 - Day 4

  2. Consumption of rescued parecoxib

    2. Consumption of rescued parecoxib 40 mg and morphine 4 mg.

    Time frame: Day 1 - Day 4

  3. Brief Pain Inventory short form (BPIsf)

    3. Using Brief Pain Inventory short form (BPIsf) to assess pain intensity and pain interference at 22 ± 0.5, 46 ± 0.5 and 70 ± 0.5 hours after the first dose.

    Time frame: Day 2 - Day 4

  4. The evaluation of adverse events

    4. The evaluation of the number and frequency of adverse events will continue until the end of the trial 120 hours after the first dose.

    Time frame: Day 1 - Day 6

  5. Patient satisfaction

    5. Patient satisfaction on day 4.

    Time frame: Day 4

  6. Assessment of ALT and AST

    6. Assessment of ALT and AST at 70.75 ± 2 hours after the first dose.

    Time frame: Day 4

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's planned 17 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 6, 2023
StartActual
Jul 25, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05842733
Lead sponsor
Sinew Pharma Inc.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jul 25, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 27, 2023

Study contacts

Cheng-Fong Mr Chen, PhD
principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine sebacate

Start the discussion